Latest Content

Nitipong Permpalung, MD, MPH, discusses how early remdesivir may reduce graft loss and cardiovascular events after COVID-19 in kidney transplant recipients.

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

Wildfire smoke from US and Canadian fires is worsening air quality, increasing asthma risks and prompting public health guidance.

A study found that elevated IL-6 and IL-17A levels were associated with greater fatigue for up to 3 years after CRC diagnosis.

In a small, placebo-controlled trial, oral semaglutide reduced heavy drinking days and craving in adults with AUD, though it missed its primary end point.

The FDA's push for faster, more diverse trials misses the real fix: experts say AI simulation and readability, not red tape, close the gap.

HIV disrupts several steps required for durable antibody production; for example, CD4+ helper T cells are depleted and functionally impaired.

Acoramidis attenuated declines in patient-reported health status through 30 months, complementing previously reported survival and hospitalization benefits.

The meta-analysis of 17 studies found that frailty was strongly associated with cognitive impairment in CKD, highlighting the need for further research to determine a causal relationship.